Suppression of VEGFR‐3 signaling inhibits lymph node metastasis in gastric cancer

• DOI: 10.1111/j.1349-7006.2004.tb03211.x
• Publication Date: 2005-08-19T10:13:18Z
• Authors: Kenji Shimizu; Hajime Kubo; Koji Yamaguchi; Kazuhiko Kawashima; Yoshihide Ueda; Koichi Matsuo; Masaaki Awane; Yasuyuki Shimahara; Arimichi Takabayashi; Yoshio Yamaoka; Seiji Satoh
• Keywords: Adult; Aged, 80 and over; Male; 0301 basic medicine; Antibodies, Monoclonal; Membrane Transport Proteins; Middle Aged; Neoplasm Proteins; 3. Good health; Mice; 03 medical and health sciences; Stomach Neoplasms; Cell Line, Tumor; Lymphatic Metastasis; Biomarkers, Tumor; Animals; Humans; Female; Immunotherapy; Lymphangiogenesis; Aged; Glycoproteins; Signal Transduction

In gastric cancer, lymph node metastasis is one of the major prognostic factors and forms basis for surgical removal local nodes. Recently, several studies have demonstrated that overexpression lymphangiogenic growth factor VEGF‐C or VEGF‐D induces tumor lymphangiogenesis promotes lymphatic in mouse models. We examined whether these processes could be inhibited naturally metastatic tumors by blocking their cognate receptor VEGFR‐3 signaling pathway. Using a orthotopic cancer model which has high frequency metastasis, we estimated vessels cancers immunostaining other specific markers, LYVE‐1 prox‐1. Then systemically administered anti‐VEGFR‐3 antibodies. This treatment resulted inhibition regional reduction vessel density primary tumors. addition, increased LYVE‐1‐positive was closely correlated with human samples cancer. Antilymphangiogenesis inhibiting provide potential strategy prevention